AbbVie is pulling out of its collaboration with Alector on the development of Alzheimer's disease candidate AL003, which aims to tackle the neurodegenerative disease by restoring reduced im
Alector has launched an $208 million stock market offering as it ramps up clinical trials with AbbVie into a drug that aims to tackle Alzheimer’s by modifying the brain’s immune system.
The 35-day US government shutdown has not just played havoc at government-run agencies – it has had a knock-on effect on the stock market because of cutbacks at the Securities and Exchange
AbbVie has agreed a new R&D deal with privately owned biotech Alector to develop novel treatments for Alzheimer's disease and other neurodegenerative disorders.
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio